Cushman & Wakefield 19th Annual Race for Hope DC Raises $2 Million - Cushman & Wakefield

Cushman & Wakefield 19th Annual Race for Hope DC Raises $2 Million

Cushman & Wakefield, a global leader in commercial real estate services, today announced that the Cushman & Wakefield 19th Annual Race for Hope DC held on Sunday, May 1, 2016, to benefit National Brain Tumor Society (NBTS) and Accelerate Brain Cancer Cure (ABC2) raised over $2 million. More than 11,000 runners, walkers, survivors and volunteers participated in this year’s event, which is the country’s largest fundraiser for the brain tumor community.

Max Wallace, CEO, Accelerate Brain Cancer Cure; David Arons, CEO National Brain Tumor Society; Roberta Liss, Mid-Atlantic Region Market Leader, Cushman & Wakefield; Jonathan Weinberg, Co-Chair Race for Hope and Board Member of ABC 2 ; Jeff Kolodin, Co-Chair of Race for Hope DC and Chairman Emeritus, NBTS; and Nike Beddow, Co-Founder, Race for Hope DC, presented a check to NBTS and ABC 2 for the 2016 Race proceeds at Freedom Plaza in Washington, DC, at an awards ceremony immediately following the race. 

“The Race for Hope DC is our highest priority charitable cause for Cushman & Wakefield in the Washington metropolitan area,” Ms. Liss said. “Our involvement started 16 years ago when one of our legacy firms’ co-founders, Pat Cassidy, fell ill with a brain tumor. While we lost Pat in 2001, our support of this cause has only grown since then. We at Cushman & Wakefield are honored to be continuing the efforts of Cassidy Turley and then DTZ, as presenting sponsor of the largest fundraiser for brain tumor research in the country,” Ms. Liss continued. “The Race for Hope provides invaluable funding for the National Brain Tumor Society and Accelerate Brain Cancer Cure as they fund new research and support for brain cancer patients. Together we are making real progress towards a cure and improving the quality of life for brain tumor patients. Cushman & Wakefield wants to thank all of our friends and clients for their continuous support of our efforts.”

David Cook, American Idol® winner, participated in the race for the eighth year and is Honorary Chair of the Race for Hope. He ran in the Race in 2009, just one day after his brother Adam died of a brain tumor.
“I’m proud to be part of Race for Hope,” said Mr. Cook. “To be around so many people who are dedicated to helping find an end to brain cancer is something that I'm honored to be a part of. We honor the memories of those who have lost their battle with brain tumors, and celebrate the survivors and family members who continue to fight the disease.”

Highlights of the 19th anniversary Race for Hope DC included a Survivor Tribute featuring over 350 brain tumor survivors who marched together towards the start line as a symbol of hope and strength in their battle against brain tumors. The Race for Hope is the culmination of a weekend of activities that also featured the On Course for Hope – In Special Memory of Bill Mattox golf tournament at Four Streams Golf Course and many team-sponsored fundraising parties.

Since its inception 19 years ago, the Race for Hope DC has raised more than $27 Million for brain tumor research and support for those affected by the disease. Each year, the Race for Hope DC helps to bring hope and attention to this often underserved brain tumor community. The need to increase research funding is more urgent than ever – there are almost 700,000 people living with a primary brain tumor diagnosis in the U.S. and within the next 12 months, more than 210,000 people in the U.S. will be diagnosed with a primary or metastatic brain tumor. 

The over $2 million raised will help ABC2 fund novel translational research and investments in early stage biotechnology companies to hasten the discovery of a cure for brain cancer, and help the National Brain Tumor Society drive strategic research for the discovery of new brain tumor treatments and a cure, as well as improve public policy to strengthen research, ensure access to essential health care services and foster expedited approvals for new potential treatments.